GlycoMimetics (GLYC) announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer ...

Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease will ...

Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment ...